Net Income (Loss) Attributable to Parent in USD of RVL Pharmaceuticals plc from Q3 2017 to Q2 2023

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
RVL Pharmaceuticals plc quarterly/annual Net Income (Loss) Attributable to Parent history and change rate from Q3 2017 to Q2 2023.
  • RVL Pharmaceuticals plc Net Income (Loss) Attributable to Parent for the quarter ending 30 Jun 2023 was -$23.9M, a 97.3% decline year-over-year.
  • RVL Pharmaceuticals plc Net Income (Loss) Attributable to Parent for the twelve months ending 30 Jun 2023 was -$68.3M, a 20.8% decline year-over-year.
  • RVL Pharmaceuticals plc annual Net Income (Loss) Attributable to Parent for 2022 was -$51.7M, a 20.4% increase from 2021.
  • RVL Pharmaceuticals plc annual Net Income (Loss) Attributable to Parent for 2021 was -$64.9M, a 18.4% increase from 2020.
  • RVL Pharmaceuticals plc annual Net Income (Loss) Attributable to Parent for 2020 was -$79.6M, a 70.6% increase from 2019.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Change (%)

RVL Pharmaceuticals plc Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2023 -$68.3M -$23.9M -$11.8M -97.3% 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2023
Q1 2023 -$56.5M -$11.6M -$4.79M -70.2% 01 Jan 2023 31 Mar 2023 10-Q 11 May 2023
Q4 2022 -$51.7M -$18.3M +$1.4M +7.11% 01 Oct 2022 31 Dec 2022 10-K 20 Mar 2023
Q3 2022 -$53.1M -$14.4M +$3.41M +19.1% 01 Jul 2022 30 Sep 2022 10-Q 10 Nov 2022
Q2 2022 -$56.5M -$12.1M +$5.62M +31.7% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023
Q1 2022 -$62.1M -$6.82M +$2.79M +29% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023
Q4 2021 -$64.9M -$19.7M +$35.2M +64.1% 01 Oct 2021 31 Dec 2021 10-K 20 Mar 2023
Q3 2021 -$100M -$17.9M -$9.23M -107% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022
Q2 2021 -$90.8M -$17.7M -$4.73M -36.4% 01 Apr 2021 30 Jun 2021 10-Q 11 Aug 2022
Q1 2021 -$86.1M -$9.61M -$6.53M -212% 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022
Q4 2020 -$79.6M -$54.9M -$28.2M -106% 01 Oct 2020 31 Dec 2020 10-K 30 Mar 2022
Q3 2020 -$51.4M -$8.63M +$104M +92.3% 01 Jul 2020 30 Sep 2020 10-Q 15 Nov 2021
Q2 2020 -$155M -$13M +$112M +89.6% 01 Apr 2020 30 Jun 2020 10-Q 16 Aug 2021
Q1 2020 -$267M -$3.08M +$3.6M +53.9% 01 Jan 2020 31 Mar 2020 10-Q 13 May 2021
Q4 2019 -$271M -$26.6M +$80.4M +75.1% 01 Oct 2019 31 Dec 2019 8-K 08 Sep 2021
Q3 2019 -$351M -$113M -$109M -3025% 01 Jul 2019 30 Sep 2019 10-Q 10 Nov 2020
Q2 2019 -$242M -$125M -$131M -2286% 01 Apr 2019 30 Jun 2019 10-Q 11 Aug 2020
Q1 2019 -$112M -$6.69M -$1.9M -39.8% 01 Jan 2019 31 Mar 2019 10-Q 12 May 2020
Q4 2018 -$110M -$107M 01 Oct 2018 31 Dec 2018 10-K 19 Mar 2020
Q3 2018 -$3.61M +$10.4M +74.2% 01 Jul 2018 30 Sep 2018 10-Q 14 Nov 2019
Q2 2018 $5.71M 01 Apr 2018 30 Jun 2018 10-Q 14 Nov 2019
Q1 2018 -$4.78M 01 Jan 2018 31 Mar 2018 10-Q 14 Nov 2019
Q3 2017 -$14M 01 Jul 2017 30 Sep 2017 10-K 28 Mar 2019

RVL Pharmaceuticals plc Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2022 -$51.7M +$13.2M +20.4% 01 Jan 2022 31 Dec 2022 10-K 20 Mar 2023
2021 -$64.9M +$14.7M +18.4% 01 Jan 2021 31 Dec 2021 10-K 20 Mar 2023
2020 -$79.6M +$191M +70.6% 01 Jan 2020 31 Dec 2020 10-K 30 Mar 2022
2019 -$271M -$161M -147% 01 Jan 2019 31 Dec 2019 8-K 08 Sep 2021
2018 -$110M -$68.4M -166% 01 Jan 2018 31 Dec 2018 10-K 19 Mar 2020
2017 -$41.3M 01 Jan 2017 31 Dec 2017 8-K 20 Dec 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.